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Methods: We reviewed the literature for functional outcomes in mild AD or mild cognitive impair-
ment (MCI) patients (distinct from combined mild-moderate/severe AD) treated with approved AD
drugs. Cognitive and functional treatment differences in mild AD patients in solanezumab EXPEDI-
TION/EXPEDITION2 studies were compared across time.
Results: Seven publications provided MCI/mild AD functional outcomes, one of which reported a
significant functional treatment effect. Secondary analyses of EXPEDITION studies suggested a
smaller functional effect of solanezumab relative to cognition. An increasing effect of solanezumab
over 18 months was shown for cognition and function.
Discussion: Function as the sole measure to demonstrate clinical meaningfulness of cognitive effects
in mild AD may have limitations. For disease-modifying treatments, point differences on cognitive
and functional scales should be qualified with duration of treatment.
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Alzheimer’s disease (AD) is primarily a disease of cogni-
tion, but it can also lead to deficits in function, including activ-
ities of daily living and behavioral abnormalities, particularly
in more advanced stages of the disease. Current evidence sug-
gests that the pathologic and clinical manifestations of AD
exist in a continuum, with the accumulation of amyloid plaque
and structural biological changes starting to occur as early as
10–20 years before the emergence of clinical symptoms [1–
4]. For clinical research purposes, the continuum of AD
progression must be categorized into narrowed and more
homogeneous stages so that disease progression and
treatment effects can be observed, measured, and compareduthor. Tel.: 11-317-433-7144; Fax: 11-317-276-
iemers@lilly.com
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i Lilly and Company. Published by Elsevier Inc. on behalf of
//creativecommons.org/licenses/by-nc-nd/4.0/).using scales with appropriate psychometric properties. These
stages include preclinical AD, prodromal AD/mild cognitive
impairment (MCI), mild AD dementia, moderate AD
dementia, and severe AD dementia.
The current AD clinical trial landscape focuses on putative
disease-modifying agents in patients with preclinical AD,
MCI, or mild AD dementia. Conversely, currently approved
AD treatments include the acetylcholinesterase inhibitors do-
nepezil, galantamine, and rivastigmine, and the N-methyl-D-
aspartate receptor antagonist, memantine for mild, moderate,
and/or severe AD dementia. While providing symptomatic
improvement, these treatments have not been shown to slow
disease progression through modification of the underlying
disease pathology [5,6]. Potential disease-modifying treat-
ments for AD are intended to slow decline rather than produce
transient improvement; conceptually, this appears as a gradu-
ally increasing benefit over time rather than the acute
improvement seen with symptomatic treatments (Fig. 1). Asthe Alzheimer’s Association. This is an open access article under the CCBY-
Fig. 1. Hypothetical effect on progression of ADwith treatments providing symptomatic improvement, slowing of disease progression, or both, compared with
placebo. Slowing of disease progression is assumed to be 50% compared with placebo. Abbreviations: AD, Alzheimer’s disease; DM, disease modifier (that is, a
treatment that modifies the underlying pathology of disease, thereby slowing its progression).
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development have gained regulatory approval.
Historically, the effectiveness of approved AD treatments
has been established not only based on an effect on cognition
but also with a coprimary outcome based on a global or func-
tional scale. The coprimary measure was intended to ensure
that the demonstrated cognitive effects were clinically
meaningful to patients and caregivers. The registration
studies for donepezil [7], galantamine [8], rivastigmine
[9], and tacrine [10] (which was withdrawn from use due
to its safety profile [11]) in combined mild-to-moderate
AD populations included coprimary cognitive and global
measures; the 11-item Alzheimer’s Disease Assessment
Scale—Cognitive subscale (ADAS-Cog11) [12,13] was
used as the measure of cognition, and the Clinician’s
Interview-Based Impression of Change plus caregiver or
the Clinical Global Impression of Change were used as the
global measures to assess the clinical meaningfulness of
cognitive effects. Although these global measures were
effective for these short-term clinical trials of symptomatic
agents, they are not appropriate for long-term disease pro-
gression studies (typically 181months) as they rely on a cli-
nician’s subjective assessment of memory and patient
performance in contrast to the baseline. The use of a func-
tional scale, which mitigates the limitations of global scales
in long-term trials, as a coprimary measure in registration
studies for currently available symptomatic drugs, has
been limited to studies of memantine in moderate to severe
AD [14].
Although symptomatic treatments were developed for pa-
tients with mild-to-moderate or moderate-to-severe demen-
tia, most current AD clinical trials are evaluating putative
disease-modifying agents in patients with preclinical AD,
MCI, or mild AD dementia; thus, an assessment of the
appropriateness of currently existing clinical rating scales,
in particular functional scales, to ensure that demonstratedcognitive effects are clinically meaningful in these earlier
patient populations is warranted. This article provides a brief
literature review of the outcomes of functional measures in
mild AD dementia and MCI subpopulations. We also
compare results of this literature review with cognitive and
functional treatment effect data from secondary efficacy re-
sults in the mild AD subpopulation from the solanezumab
phase 3 EXPEDITION and EXPEDITION2 studies
[15,16]. Additionally, because clinical meaningfulness is
sometimes assessed simply as a minimal point difference
between active treatment and placebo on a particular scale
[17–19], we assess point differences and effect sizes in
cognitive and functional scales at various times during the
EXPEDITION and EXPEDITION2 clinical trials. As
predicted in the scientific literature [20] and as shown in
Figure 1, for a hypothetical disease-modifying treatment,
the point difference between active treatment and placebo
and the effect size is not constant but increases with duration
of treatment.2. Methods
2.1. Literature search
To assess the effect of approved symptomatic treatments
on activities of daily living (ADLs) in patients with mild AD
dementia, we reviewed the literature on clinical trials of
currently approved treatments for AD. A Medline search
([“Alzheimer Disease” or “Mild Cognitive Impairment”]
and “Activities of Daily Living” and [“donepezil” or “gal-
antamine” or “rivastigmine” or “memantine”]) that included
publications to October Week 5 2015 was conducted. Those
publications were limited to reports that provided results
from randomized, placebo-controlled studies for MCI and/
or mild AD patients separately (not combined with moderate
or severe AD patients). Treatment effect sizes (treatment
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lated for publications that provided the required data for both
cognitive and functional outcomes.
2.2. EXPEDITION and EXPEDITION2 secondary
outcomes
The primary outcomes for the EXPEDITION and EXPE-
DITION2 trials for solanezumab have been previously re-
ported [15]. These studies used the ADAS-Cog and the
mini mental state examination (MMSE) as cognitive mea-
sures and the Alzheimer’s Disease Cooperative Study—Ac-
tivities of Daily Living Inventory (ADCS-ADL) and the
Resource Utilization in Dementia (RUD-Lite) as functional
measures. Although the coprimary outcomes (ADAS-Cog
and ADCS-ADL) in the combined mild-to-moderate AD
subjects were not positive, in a secondary analysis, mild
AD subjects treated with solanezumab for 18 months indi-
cated a slowing in cognitive decline of approximately 34%
and a slowing in functional decline of approximately 18%
using the instrumental subscale of the ADCS-ADL
(ADCS-iADL) when comparing baseline to endpoint
changes [16]. We estimated the treatment point differences
and effect sizes (treatment difference divided by pooled
standard deviation) on the cognitive and functional scales
using mixed-model repeated measures (MMRM) at several
time points during the 18-month treatment period in mild
AD dementia patients from the EXPEDITION studies and
compared them across time to assess the time dependence
of the difference between active treatment and placebo.3. Results
3.1. Literature review
The search criteria yielded 183 publications, and just
seven reported functional results specifically for patients
with MCI or mild AD (separately from moderate and/or se-
vere AD) from studies of an approved AD drug (Table 1). Of
these seven publications, only one reported a statistically
significant drug effect on a functional measure: when evalu-
ating three trials of rivastigmine, Potkin et al. [21] reported a
statistically significant change in the Progressive Deteriora-
tion Scale (PDS), a secondary measure of function, in pa-
tients who completed 26 weeks of treatment and who were
classified as mild based on a Global Deterioration Scale
(GDS) of 3 or less. Although later analyses of the same
studies showed statistically significant effects on the
ADAS-Cog in mild (MMSE 22), moderate (MMSE 16
to 22), and severe (MMSE 15) AD groups and statistically
significant effects on function, as measured by the PDS in
the moderate and severe groups, the difference on function
in the mild AD group failed to reach statistical significance
in these analyses [22]. In addition to the difference in
severity classification methodology, the later analyses also
did not limit the analyses to patients who completed
26 weeks of treatment.Similarly, the other five studies that reported results for
MCI or mild AD patients did not demonstrate an effect on
function even when an effect on cognition was shown. In a
study of galantamine treatment assessing caregiver time, dif-
ferences versus placebo were statistically significant for pa-
tients with moderate dementia (MMSE 11 to 18) and greater
than for patients with mild dementia (MMSE 19 to 24, sta-
tistical significance not reported) [23]. In another study of
galantamine among mild-to-moderate AD patients (MMSE
10 to 22), the largest and only statistically significant
treatment-versus-placebo difference in ADCS-ADL scores
occurred in patients with more severe dementia (MMSE
10 to 15) at baseline; additionally, in placebo-treated pa-
tients, worsening of ADCS-ADL scores was greater in pa-
tients with more severe dementia [24]. In a study of
donepezil and vitamin E in patients with MCI, statistically
significant differences relative to placebo in a modified
ADAS-Cog were demonstrated but without significant dif-
ferences in the ADCS-ADL (modified for use in MCI pa-
tients) [25]. Gauthier et al. [26] combined results from six
studies of donepezil to assess individual ADL items among
patients stratified by disease severity. In an analysis of over
1000 mild (MMSE 18 to 26) patients, no statistically signif-
icant differences in any instrumental or basic ADL items
were found compared with placebo, although differences
were observed in the moderate (MMSE 10 to 17) patients.
Farlow et al. [27] compared response of two doses of a riva-
stigmine patch, one dose of rivastigmine capsule, and pla-
cebo. In their analysis, significant changes in ADCS-ADL
scores were found for moderate (MMSE 16 to 18) and
moderately severe (MMSE 13 to 15) patients, but no differ-
ences versus placebo were found for mild (MMSE 19 to 25)
patients. Thus, our literature review suggests that in studies
of treatments recognized as having clinical benefits, the
treatment effect on ADLs in combined mild plus moderate
populations has been driven by the moderate AD patients;
treatment effect on ADLs has been difficult to demonstrate
in patients with mild AD dementia alone.3.2. Secondary analyses of phase 3 solanezumab studies
For both cognitive and functional scales assessed in the
solanezumab EXPEDITION studies, the point differences
between active treatment and placebo and effect sizes grad-
ually increased over the 18-month treatment duration
(Table 2). Thus, an assessment of the point differential be-
tween active treatment and placebo as well as the effect
size must be qualified with the time point of the assessment.
Effect sizes on the cognitive scales were higher than those on
the functional scales at all time points.
Of the seven articles that reported functional outcomes
from studies of an approved AD drug in mild AD and
MCI patients, only Petersen et al. [25] also provided cogni-
tive outcomes and the data necessary to calculate effect size.
In this reported comparison of donepezil and placebo over
3 years in MCI patients, the effect sizes for the cognitive
Table 1
Summary of publications reporting analyses of effects of approved AD medications on function in mild AD populations
Citation Treatments (N)
Analysis
population Design Duration Findings by baseline severity
Potkin
et al. 2002 [21]
Rivastigmine (158),
placebo (180)
Mild AD Pooled analysis of 3 randomized,
double-blind, placebo-controlled
studies*
6 mo Statistically significant change in the
PDS when classifying subjects as
mild based on a GDS of 3.
Sano
et al. 2003 [23]
Galantamine (261),
placebo (258)
Mild AD Pooled analysis of 2 randomized,
double-blind, placebo-controlled
studies
6 mo Differences in caregiver time vs
placebo were greater and
statistically significant in subjects
with moderate dementia (MMSE
11 to 18) relative to thosewith mild
dementia (MMSE 19 to 24, not
significant).
Galasko
et al. 2004 [24]
Galantamine (424),
placebo (235)
Mild AD Randomized, double-blind, placebo-
controlled study
5 mo Largest and only statistically
significant treatment vs placebo
difference in ADCS-ADL scores
occurred in subjects with more
severe dementia at baseline
(MMSE 10 to 15). In placebo
group, worsening of ADCS-ADL
scores was greater in those with
more severe dementia.
Kurz
et al. 2004 [22]
Rivastigmine (365),
placebo (288)
Mild AD Pooled analysis of three randomized,
double-blind, placebo-controlled
studies*
6 mo Among mild AD patients (MMSE 22
to 26) at 26 weeks, a statistically
significant difference between
rivastigmine and placebo on
ADAS-Cog was observed, but the
difference in PDS was not
significant.
Petersen
et al. 2005 [25]
Donepezil (253),
placebo (259),
vitamin E (257)
MCI Randomized, double-blind, placebo-
controlled study
3 y Statistically significant differences vs
placebo in a modified ADAS-Cog
were demonstrated with donepezil
in the first 18 mo but without
significant differences in the
ADCS-ADL (modified for use in
MCI patients) at any time point.
Gauthier
et al. 2010 [26]
Donepezil (702),
placebo (453)
Mild AD Pooled analysis of 6 randomized,
double-blind, placebo-controlled
studies
6 mo No statistically significant differences
in any instrumental or basic ADL
items were found compared with
placebo among those with mild
disease (MMSE 18 to 26), whereas
changes were found in those with
moderate (MMSE 10 to 17) and
severe (MMSE 5 to 9) disease.
Farlow
et al. 2011 [27]
Rivastigmine (256),
placebo (92)
Mild AD Randomized, double-blind, placebo-
controlled study
6 mo Significant changes in ADCS-ADL
scores were found for those with
moderate (MMSE 16 to18) and
moderately severe (MMSE 13 to
15) disease, but no differences vs
placebo were found for mild
disease (MMSE 19 to 25).
Abbreviations: AD, Alzheimer Disease; PDS, Progressive Deterioration Scale; GDS, Global Deterioration Scale; MMSE, mini mental state examination;
MCI, mild cognitive impairment; ADCS-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory; ADAS-Cog, Alzheimer’s Disease
Assessment Scale-Cognitive subscale; ADL, activity of daily living.
*Potkin et al. (2002) and Kurz et al. (2004) reported results from analyses of the same three studies.
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at their maximum value at the initial post-baseline time point
of 6 months. A comparison of effect sizes over time for the
solanezumab EXPEDITION studies and the Petersen done-
pezil study are provided in Fig. 2.4. Discussion
Changes in global or functional measures have tradition-
ally been used to ensure the clinical relevance of a cognitive
treatment effect in AD trials. Global or functional measures
were used for assessing clinical meaningfulness in clinical
Table 2
Changes in cognitive and functional measures over time; solanezumab
EXPEDITION and EXPEDITION2 studies, pooled in the mild population
LS mean change from
baseline*
Week Placebo Solanezumab Difference
P
valuey
Effect
size
Cognitive measures
ADAS-Cog14 28 0.63 0.34 20.29 .465 .036
52 3.36 2.29 21.08 .025 .119
80 6.21 4.08 22.13 .001 .191
MMSE 28 20.30 20.18 0.12 .468 .031
52 21.43 21.01 0.42 .051 .097
80 22.76 21.83 0.93 .001 .190
Functional measures
ADCS-iADL 28 21.73 21.54 0.19 .608 .025
52 23.77 22.98 0.79 .100 .088
80 26.77 25.56 1.21 .045 .116
RUD-lite
iADL
28 20.02 20.08 20.06 .716 .018
52 0.21 0.07 20.13 .419 .038
80 0.53 0.26 20.27 .174 .073
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale–
Cognitive subscale; ADCS-iADL, Alzheimer’s Disease Cooperative Study
Activities of Daily Living Inventory instrumental subscale; LS, least
squares; MMSE, mini mental state examination; RUD-Lite iADL, resource
utilization in dementia-lite instrumental activities of daily living item.
*Least squares (LS) mean change from baseline to endpoint, mixed-
model repeated measures (MMRM).
yP value for the comparison of placebo and solanezumab LS mean
change, MMRM.
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severe patient populations, typically ranging in duration
from 3 to 6 months. Given that AD research has evolved
to focus more on patients earlier in the disease continuum,
testing investigational disease-modifying drugs in studies
lasting at least 18 months, the results of this literature review
and the secondary outcomes of the solanezumab EXPEDI-
TION studies suggest that corresponding changes in the
methodology for demonstrating clinical meaningfulness
may be warranted for disease-modifying treatments in
mild patient populations.Fig. 2. Effect sizes of treatment versus placebo over time. Solanezumab data are
population using the ADAS-Cog14 and the ADCS-iADL. Donepezil data are deriv
ADAS-Cog13 and the ADCS-MCI-ADL. Calculations were done assuming the valu
AD, Alzheimer disease; ADAS-Cog, Alzheimer’s Disease Assessment Scale—C
Activities of Daily Living Inventory; MCI, mild cognitive impairment.Alternate outcome measures in trials of MCI patients
have been recommended previously [28]; the proposed pri-
mary outcome measure was cognition, with ADLs and
related measures proposed as secondary outcomes as they
are less likely to be impaired. Moreover, in recognition of
the shifting focus of clinical research and the challenges
associated with accurately measuring functional or global
impairments using existing measurement tools, draft guid-
ance from FDA in 2013 [29] on developing treatments for
early AD states that among patients on the AD continuum
closest to overt dementia (prodromal AD or MCI due to
AD), use of a composite endpoint validated in early stage
patients that incorporates both cognition and function is
appropriate. For the “dementia stage” of AD, including
mild, moderate, and severe dementia the draft guidance
does, however, reiterate the previously established require-
ments for the use of coprimary outcomes reflecting both
cognitive effect and functional or global effects. The uncer-
tainty in the field regarding use of currently available func-
tional measures was captured at a meeting of the
Alzheimer’s Association’s Research Roundtable in 2013,
where the need for improved cognitive and functional
outcome measures for patients with preclinical AD and
MCI due to AD was addressed. Given the uncertainties in
the field, a single “gold standard” test of function could
not be determined. A consensus agreement from a panel
discussion indicated that scales may be assessed primarily
based on broad psychometric properties, and those proper-
ties could be used to determine if a particular scale is fit for
a particular purpose [30].
As stated previously, of the 183 manuscripts identified in
our search for functional outcomes in patients treated with
currently approved symptomatic AD treatments, only seven
actually reported these results specifically for an MCI or
mild AD population, and only one of these seven publica-
tions reported an effect of an approved AD treatment on
function. These findings suggest that in studies of approved
AD treatments generally recognized as having clinical ben-
efits, the treatment effect on ADLs in combined mild andfrom the EXPEDITION and EXPEDITION2 studies in the pooled mild AD
ed from Table 2 of the Petersen et al. [25] donepezil MCI study that used the
es in Table 2 are mean change plus/minus standard deviation. Abbreviations:
ognitive subscale; ADCS-iADL, Alzheimer’s Disease Cooperative Study
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patients with moderate dementia. Consistent with our litera-
ture review, the secondary analyses in mild patients partici-
pating in the phase 3 solanezumab EXPEDITION and
EXPEDITION2 studies demonstrated an effect on cognition
with a smaller effect on iADLs.
Although relationships between cognitive and functional
changes in AD are not well understood, it has been theorized
that cognitive decline precedes functional decline [31]. An
analysis of the correlation between raw cognitive and func-
tional scores across the mild and moderate AD patients
participating in the EXPEDITION studies demonstrated
that correlation increases steadily over time. In mild AD
EXPEDITION patients, cognition (measured by ADAS-
Cog14) was more highly correlated with iADLs than with
bADLs, whereas in moderate AD patients, the correlations
with iADLs and bADLs were much more similar [32].
Observational studies have shown that patients with milder
disease have slower rates of decline in ADLs [31], and in a
study of mild AD patients, Park et al. [33] noted that of pa-
tients with no functional impairment at baseline, 56% had no
functional loss after 1 year, despite worsening of cognitive
scores. Consistent with observational studies, moderate
(MMSE 14 to 20) placebo-treated patients in a 24-week
study of cerebrolysin showed worsening in Disability
Assessment in Dementia (DAD) scale scores, whereas
DAD scores in mild (MMSE 21 to 25) placebo-treated pa-
tients were essentially unchanged [34]. Likewise, patients
who are cognitively impaired but do not meet criteria for de-
mentia have less decline in ADLs than patients with mild AD
[35]. Finally, additional analyses using sophisticated statisti-
cal techniques are now emerging that suggest cognitive
decline precedes and predict functional decline [36,37].
Taken together and consistent with findings from our
literature review, these data suggest that for patients earlier
in the continuum of AD, treatment effects on function
would be more difficult to demonstrate relative to
cognitive effects. Reviews of AD trials broadly have
concluded that the treatment effect size for functional
outcome measures is small [38], and functional measures
tend to be less responsive to changes than cognitive or global
measures [39].
Across many disease states, the clinical meaningfulness
of a therapeutic effect may be judged by the point difference
or effect size on a particular scale. However, with a disease-
modifying therapy, point difference and effect size would be
expected to increase over time, as observed in the 18-month
EXPEDITION studies (Table 2). Thus, for a disease-
modifying treatment, a threshold point difference or effect
size must also be accompanied by the duration of treatment
necessary to achieve that effect. Given a range of clinical
trial durations for patients with mild AD dementia, MCI or
preclinical AD, and the use of different scales in these
studies, a consensus regarding duration of treatment and
point differences/effect sizes may be difficult to achieve.
Interestingly, data derived from cognitive and functionaloutcomes of donepezil and placebo-treated MCI patients
provided in Petersen et al. [25] suggest effect sizes for this
symptomatic drug do not increase over time.
Clinical meaningfulness might be judged by a number of
approaches independent of specific point differences on a
particular instrument or scale. Evidence of disease modifica-
tion alone might, in part, support the clinical meaningfulness
of a treatment. Such evidence could be supported by
biomarker changes, a delayed start analysis [40], or an
increasing effect over time during the double-blind portion
of the trial. Slope analysis, which has been proposed to
demonstrate slowing of decline [41,42], is another
statistical approach that has appeal in its intuitiveness and
illustrative value (i.e., Fig. 1). Slope analysis, however, re-
quires an assumption of linear decline in disease, which
has been the focus of continued research in the field, espe-
cially for studies of long duration [6,43,44]. Finally,
advanced statistical approaches, including path analysis
[37] can be used to show that treatment effects on function
are driven by a primary effect on cognition.
In conclusion, the published literature suggests that in
mild AD and MCI patients, using currently available, well-
recognized clinical scales in studies of treatments generally
accepted to have beneficial effects, cognitive treatment ef-
fects are more likely to be demonstrated than functional
treatment effects. A fundamental question that cannot yet
be answered is whether patients in the earlier stages of the
AD continuum have fewer functional deficits, or whether
currently available scales are inadequate to measure these
deficits given ceiling effects. As evidenced by our literature
review, very little research has been reported to specifically
address this point thus far. When considered in context of the
historical requirement that AD treatment effectiveness be es-
tablished with a coprimary global or functional scale, this
conclusion has significant implications for AD treatment
research; specifically that reliance on function as the sole
measure to demonstrate clinical meaningfulness of cognitive
effects should be reconsidered. A comparison of the cogni-
tive and functional effects of solanezumab in secondary an-
alyses of the EXPEDITION studies is consistent with this
hypothesis. Use of specific point differentials in trials of
disease-modifying drugs to assess clinical meaningfulness
is also likely to be problematic given their time dependence
and the variety of available scales. Thus, use of a functional
scale should be considered as only one of several methods to
assess clinical meaningfulness for patients early in the con-
tinuum of ADwho are given treatments intended to slow dis-
ease progression. More data and discussion are needed in
this evolving characterization of AD progression and in
the assessment of treatment effects.Acknowledgments
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1. Systematic review: Authors assessed scientific litera-
ture and secondary analyses of the 18-month,
placebo-controlled periods in solanezumab phase 3
EXPEDITION and EXPEDITION2 studies to clarify
utility of functional outcomes in determination of
clinical meaningfulness of treatments for mild AD
and MCI.
2. Interpretation: Regulatory guidance currently sug-
gests function is the onlymethod to demonstrate clin-
ical meaningfulness of a cognitive effect for putative
disease-modifying agents in mild AD; however, this
guidance is based on historic studies of symptomatic
agents conducted in combined mild-moderate or
severe AD populations. To our knowledge, a func-
tional effect has only been demonstrated for mild
AD-only or MCI population in one published study
of an approved AD drug. Secondary outcomes from
the first phase 3 solanezumab study in mild AD pa-
tients were consistent with this observation.
3. Future directions: With increasing focus on earlier
stages of AD, function as the sole mechanism for
determining clinical meaningfulness may have sub-
stantial limitations.
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